



CTLA4-Ig-modified dendritic cells inhibit lymphocyte-mediated alloimmune responses and prolong the islet graft survival in mice

Dao-Feng Yang^{a,1}, Wen-Hong Qiu^{b,1}, Hui-Fen Zhu^c, Ping Lei^c, Xue Wen^c, Hong Dai^c, Wei Zhou^c, Guan-Xin Shen^{c,*}

^a Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China

^b Medicine and life Science College of Jiangnan University; 430056, Wuhan, China

^c Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China

ARTICLE INFO

Article history:

Received 16 February 2008

Received in revised form 30 April 2008

Accepted 2 May 2008

Keywords:

CTLA4-Ig

Dendritic cell

IDDM

Islet transplantation

Immune tolerance

ABSTRACT

The induction of antigen specific tolerance is critical for prevention and treatment of allograft rejection. In this study, we transfected CTLA4-Ig gene into dendritic cells (DCs), and investigated their effect on inhibition of lymphocyte activity in vitro and induction of immune tolerance on pancreatic islet allograft in mice. An IDDM C57BL/6 murine model induced by streptozotocin is as model mouse. The model mice were transplanted of the islet cells isolated from the BALB/c mice to their kidney capsules, and injected of CTLA4-Ig modified DCs (mDCs). The results showed that mDCs could significantly inhibit T lymphocyte proliferation and induce its apoptosis; whereas, unmodified DCs (umDCs) promoted the murine lymphocyte proliferation. Compared with injection of umDCs and IgG1 modified DCs, the injection of mDCs prolonged IDDM mice's allograft survival, and normalized their plasma glucose (PG) levels within 3 days and maintained over 2 weeks. The level of IFN- γ was lower and the level of IL-4 was higher in mDCs treated recipient mice than that in control mice, it indicated that mDCs led to Th1/Th2 deviation. After 7 days of islet transplantation, HE stain of the renal specimens showed that the islets and kidneys were intact in structure, and islet cells numbers are increased in mDCs treated mice. Our studies suggest that DCs expressing CTLA4-Ig fusion protein can induce the immune tolerance to islet graft and prolong the allograft survival through the inhibition of T cell proliferation in allogeneic mice.

© 2008 Published by Elsevier B.V.

1. Introduction

The American Diabetes Association (ADA) estimates that more than 20 million people in the United States, or 7% of the population, have diabetes mellitus (DM), and that one in three Americans born in 2000 will develop diabetes sometime during their lifetime. Currently more than 230 million people live with DM worldwide. The current therapeutic protocols of DM include exogenous insulin supplement and stimulation of endogenous insulin. Pancreatic islet cell transplantation for the treatment of DM is still a great challenge until now, but it is a promising therapy for IDDM [1]. It is well known that the transplanted islet cells are very sensitive to various stimulations and easily rejected by recipient immune systems. Therefore, a new technique that can only induce the recipient immune tolerance to

transplanted islet but not affect the immune response to other antigens is anticipated.

Dendritic cells (DCs) have several functions in innate and adaptive immunity, they play a major role in antigen presentation and T cell priming and are therefore crucial in stimulating the primary response of transplant immune [2–4]. They are potentially powerful tools for the therapeutic manipulation of immune reactivity in allergic diseases, cancers, infectious diseases, and allograft rejection [2–7]. The antigen presentation may be blocked or inhibited by the modification of the genes encoding costimulatory molecules and cytokines, thus, the allotopic immune tolerance is induced. CTLA4-Ig is a recombinant fusion protein of the ectodomain of cytotoxic T lymphocyte associated antigen (CTLA4) and the constant domain of human immunoglobulin. *In vitro* and *in vivo* studies have demonstrated that CTLA4-Ig can block the B7/CD28 costimulatory pathway and prevent the rejection of xenogeneic islets and/or allogeneic corneal, skin, liver, cardiac and islet graft [8–11].

In this study, we transfected CTLA4-Ig gene into DCs through liposome Lipofectamine to obtain gene modified DCs (mDCs) that could stably express fusion protein CTLA4-Ig. Then we evaluated their

* Corresponding author. Hangkong Road 13, Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China. Tel.: +86 27 83692611; fax: +86 27 83693500.

E-mail address: myjsz@mails.tjmu.edu.cn (G.-X. Shen).

¹ These authors contributed equally to this work.




Fig. 1. SDS-PAGE analysis of CTLA4-Ig expression in DC culture supernatant. 1: protein marker (M_r); 2: culture supernatant of pG/CTLA4-Ig-transfected DCs; 3: culture supernatant of untransfected DCs.

impacts on lymphocyte proliferation and apoptosis in vitro, investigated their effects on allogeneic islet transplant in IDDM mice.

2. Materials and methods

2.1. The animals and their induction of hyperglycemia by STZ

Eight- to 10-week-old BALB/c and C57BL/6 male mice, weighing 18–22 g, were purchased from the Center of Experimental Animals, Hubei Academy of Medical Science. BALB/c mice were used as donors, C57BL/6 mice as recipients. Mice were housed in an air-conditioned environment, with a 12-hour light-dark cycle, and fed a regular unrestricted diet. All experiments were approved by the local government authorities.

Diabetes was induced in C57BL/6 mice by an intravenous injection of streptozotocin (Sigma, St. Louis, MO) at a concentration of 220mg/kg [12]. The plasma glucose (PG) levels were measured by a Beckman glucose analyzer (Roche Accu Check III). Three days later, the non-fasting PG was measured daily for 5 days. The IDDM C57BL/6 model was thought to be successfully created if the PG level was over 16.65 mmol/L for at least 3 consecutive days.

2.2. Transfection of CTLA4-Ig gene into DCs

The mouse thymic DCs were kindly provided by Prof. Chen Weifeng (Department of Immunology, Beijing Medical University). Plasmid pG/CTLA4-Ig was transfected into the DCs by liposome Lipofectamine (Invitrogen). The positive cells were screened by mycophenolic acid (Sigma) and cloned by limiting dilution. The CTLA4-Ig fusion protein was identified by SDS-PAGE and indirect enzyme-linked immunoabsorbent assay (ELISA).

2.3. Detection of lymphocyte apoptosis

The lymphocytes of healthy C57BL/6 mice were prepared by a sterile method and were used as responders (1×10^5 /ml). CTLA4-Ig modified DCs (mDCs) or unmodified DCs (umDCs) pretreated with mitomycin C (Sigma) were employed as stimulators (1×10^5 /ml). After the lymphocytes were cocultured with pretreated mDCs or umDCs for 6 days, the apoptosis was detected by ELISA (Roche) as described previously [13]. In brief, the lymphocytes, cultured in 6-well culture plates, were directly lysed with a lysis buffer, after which the cytosolic oligonucleosome was quantified using biotin-labeled mouse monoclonal anti-histone antibody as the capturing antibody, peroxidase-conjugated




Fig. 2. The lymphocyte proliferation in different sensitized mice (umDCs and mDCs) and unsensitized mice when stimulated by mDCs and umDCs. The results are shown as mean \pm SD; *OD mean values as stimulated by mDCs were significantly less than these as stimulated by umDCs (* $p < 0.01$).




Fig. 3. Survival days of transplanted mice (survival rate, %) Group 1: islets graft control; Group 2: umDCs treated recipients; Group 3: IgG1 modified DCs treated recipients; Group 4: mDCs treated recipients; Group 5: healthy mice.

mouse monoclonal anti-DNA antibody as the detecting antibody, and ABTC (2,2'-azino-di[3-ethylbenzthiazolin-sulfonate]) as the developing agent. The relative increase in nucleosomes in the cytoplasm was expressed as an enrichment factor, which was calculated as the ratio of the specific absorbance of lysates at 405 nm to that of untreated cells.

2.4. Lymphocyte proliferations induced by different DCs

Modified DCs or umDCs were intraperitoneally injected into C57BL/6 mice at a dose of 1×10^7 /mouse. Five days later, the animals were sacrificed and their spleen cells were harvested to isolate mononuclear cells. $100 \mu\text{l}$ mononuclear cells (5×10^6 /ml) and $100 \mu\text{l}$ mitomycin C pretreated mDCs or umDCs (5×10^4 /ml) were planted into 96-well plates, and incubated at 37°C for 7 days. Proliferation was assessed by methyl thiazolyl tetrazolium (MTT) chromatometry. The OD value was measured at 570 nm by a microtiter plate reader (Bio-Rad, Tokyo, Japan).

2.5. Islet transplantation

Pancreatic islets were isolated from the male BALB/c mice by collagenase technique [14]. After washed twice, the islets were cultured in 1 ml Krebs-Ringer bicarbonate buffer with HEPES and their insulin secretory function was assayed by immunoradioassay [15]. Male IDDM model C57BL/6 mice were served as recipients. The islet cells were grafted under the left kidney capsule of recipient mice at a dose of 600 islets/mouse. This technique is followed from the renal subcapsular islet transplantation as reported previously [16]. Briefly, after an appropriate anesthesia with pentobarbital sodium, the mice were placed on the right lateral position, by which the left kidney contour was visualized. A small skin incision was made and the abdomen was opened. The left kidney was protruded extraperitoneally through the incision manually. A small horizontal incision was made on the capsule close to the lower pole of the kidney. A pocket space beneath the kidney capsule was created toward the upper pole of the kidney, where pancreatic grafts were introduced. The kidney bearing the grafts was placed back into the abdomen after the completion of transplantation, and the incision was closed by layers.

Grouping of transplanted mice: the islet recipient mice were allocated into four groups and treated with: I) islet transplant only (6 mice); II) islet transplant followed by injection of mDCs through the vena caudalis at the same day (8 mice); III) islet transplant followed by injection of IgG1 modified DCs (5 mice); IV) islet transplant followed by injection of umDCs (6 mice). The number of DCs in above groups was 1×10^7 per mouse. Eight healthy C57BL/6 mice without islet transplant were employed as controls.

2.6. Observation and cytokine quantification in the transplanted mice

After transplantation, the survival time of recipient mice was recorded. Body weights and PG levels were monitored on a daily basis. Normoglycemia was defined as




Fig. 4. The profiles of PG levels in different islet recipient mice. Group 1: graft control mice; Group 2: umDCs treated recipients; Group 3: mDC-IgG1 treated recipients; Group 4: mDCs treated recipients.




Fig. 5. The serum insulin levels and glucose tolerance test after ip injection of glucose in mDC treated grafted mice. A: serum insulin levels in mDC treated graft mice and healthy control mice; B: blood glucose profiles in both groups on days 5 and 15.

PG no greater than 8.4 mmol/L. In normoglycemic recipients, insulin secretions were assessed by radioimmunoassay on days 5 and 15, and glucose tolerance tests were performed on day 15 according to the procedure reported previously [17]. Briefly, the animals were fasted one night before the experiment. 1.0 g/kg of glucose was administered intraperitoneally, and serum insulin concentration was measured at 10 min and plasma glucose was detected at 0, 15, 30, 60, 90 and 120 min after glucose challenge. On days 5 and 15, serum IL-4 and IFN- γ levels in mDCs treated recipient mice and umDCs treated mice were measured using ELISA kit (Jingmei Biotech Co., Ltd), according to the manufacturer's instructions.

2.7. Immunohistochemical stain of the transplanted islets

The kidneys from the recipient mice were embedded in paraffin and sectioned at 4 μ m intervals. The sections were stained with hematoxylin-eosin or processed for immuno-peroxidase histochemistry with antibodies specific for insulin, then studied under the microscope.

2.8. Statistics analysis

The data were shown as mean \pm standard deviations. *t*-test was used to compare the difference between two groups. Differences between groups were considered significant at $p < 0.05$.

3. Results

3.1. Screening of transfected DCs and the expression of fusion protein in the supernatant

Plasmid pG/CTLA4-Ig was transfected into DCs via liposome Lipofectamine, 72 h later, the culture wells were added 100 mg/L mycophenolic acid to screen transfected DCs. Two weeks later, we obtained the positive clones of pG/CTLA4-Ig transfected DCs. ELISA showed that the OD value of mDC supernatant was similar to that of human IgG which served as positive control. A specific protein band at 55–66 kD, identical to CTLA4-Ig fusion protein, was displayed on the gel when positive DC supernatant was analyzed by SDS-PAGE; no corresponding band was displayed when untransfected DC supernatant was analyzed (Fig. 1). It indicated that expression vector pG/CTLA4-Ig had been transfected into DCs and the transfected cells were able to secrete the CTLA4-Ig fusion protein.

3.2. Effects of mDC on apoptosis and proliferation of allotype lymphocytes

The lymphocyte apoptosis was measured by ELISA. The enrichment factor was proportional to the apoptotic cells. The results showed that the enrichment factor was 2.37 ± 0.38 when umDCs was used as stimulatory cells and 4.26 ± 0.53 when mDCs were used as stimulatory cells, indicating that mDCs induce significant higher lymphocyte apoptosis than umDCs ($p < 0.05$, $n = 4$).

The lymphocyte proliferations induced by mDCs decreased markedly in both sensitized mice and unsensitized mice, their OD₅₇₀ values were lower than those in mice induced by the umDCs. OD₅₇₀ value was the lowest in mDC sensitized mice when the lymphocytes were induced by mDCs, and highest in umDC sensitized mice when the lymphocytes were induced by umDCs (Fig. 2).

3.3. The survival of transplanted mice and their PG levels

Transplanted IDDM mice injected with umDCs, IgG1 modified DCs and mDCs survived for 10.17 ± 1.60 days, 10.40 ± 1.67 days and 25.50 ± 13.60 days, respectively. Allograft control group survived for 10.15 ± 2.07 days (Fig. 3). The results demonstrated that mDCs injection prolonged the graft survival evidently, compared with umDCs and IgG1 modified DCs injection ($p < 0.01$).

The transplantation outcome was evaluated by monitoring PG levels daily. It was considered successful if PG remained lower than 11.1 mmol/L for over 3 days. The graft failure was diagnosed by relapse of hyperglycemia (> 11.1 mmol/L) for more than 3 consecutive days. The PG levels in mDCs treated mice decreased to less than 11.1 mmol/L

since 3 days after transplantation and remained in normal range (6.11–9.50 mmol/L) for over 2 weeks. But those in the mice treated with umDCs and IgG1 modified DCs elevated to 11.89 ± 2.86 mmol/L and 12.10 ± 2.58 mmol/L on day 5 respectively; indicative of a graft failure. (Fig. 4).

3.4. The results of insulin secretion test and glucose tolerance test in transplanted mice

The insulin secretion test was carried out in the mice whose PG normalized 5 and 15 days after transplantation and the healthy control mice. The insulin secretion reached the peak at 10 min after injection of glucose. The results showed that the insulin secretion in PG recovery recipients was similar to the healthy mice on day 5 and was slightly lower than that in healthy ones on day 15 ($p > 0.05$). The glucose tolerance test displayed that PG profiles resembled in both groups after glucose challenge (Fig. 5).

3.5. Cytokines in the transplanted mice

The production of IFN- γ was obviously inhibited in mDC mice with normal PG level. The level of IFN- γ in mDC mice was significantly lower than that in umDC mice; whereas, the level of IL-4 was higher than that in umDC mice ($p < 0.05$) (Fig. 6).

3.6. The histochemical stain of the allografts

HE stain of renal specimens was conducted in IDDM mice 7 days after transplantation. In the islet specimens from the IDDM mice treated with umDCs and IgG1 modified DCs, there were numerous inflammatory cells infiltrating and the islets were destroyed. However, in mice treated with mDCs, the islet structures remained intact, the grade of mononuclear cell infiltrations into the grafts was minor, and their kidney structure was normal. The kidneys to immunohistochemical staining with anti-insulin showed that more cells stained positively for insulin in mDCs treated mice than that in IgG1 modified DCs treated mice (Fig. 7).

4. Discussion

Insulin-dependent type 1 diabetes mellitus (IDDM) is caused by autoimmune destruction or dysfunction of the insulin secreting cells mediated by T lymphocytes and antibodies recognizing pancreatic islet cell antigens. In this disease, the insulin secretion decreases or




Fig. 6. Cytokines production in islet allografts. The expressions of IFN- γ and IL-4 in serum from recipient C57BL/6 mice treated with mDCs and umDCs were assessed by ELISA on days 5 and 15. Results are expressed as mean \pm SD for three individual experiments.




Fig. 7. Comparison of islet allograft histology in recipients from mDCs and IgG1-DCs treatment groups. Line 1, hematoxylin/eosin staining (H&E). Line 2, immunoperoxidase staining for antibodies to insulin (magnification $\times 100$).

suspends because the islet β cells are impaired by pathogenic autoimmune CD4⁺Th1 and CD8⁺T recognizing islet β cell autoantigens, such as glutamic acid decarboxylase (GAD65), islet antigen-2 or islet cell antibody 512 (ICA512) and insulin related antigen [18–20].

T cells are major effector cells in the allograft rejection. CD28 on T cells and B7-1/B7-2 on APCs are two important costimulatory molecules to activate T lymphocytes [21,22]. Blocking or inhibiting the transmission of costimulatory receptor signals and antigen presentation are efficient ways to induce the specific immune tolerance. CTLA4 is a negative-regulator of T cell activation by inhibiting T lymphocyte proliferation and inducing its apoptosis by blocking the co-stimulatory pathway [8]. Evidences have demonstrated that the immunosuppressive molecules modified DCs could induce the alloantigen-specific T cell anergy and prolong allograft survival [23–25]. In this study, we demonstrated that CTLA4-Ig modified DCs were able to stably express the CTLA4-Ig fusion protein. As a result, the lymphocyte proliferation induced by mDCs was obviously less than that induced by umDCs, because the activation of the allotype antigen-specific T cells was inhibited and followed by a long-term immune tolerance. The responsibility of murine T cells sensitized by mDCs to allotype DC stimulation *in vitro* was compromised, whereas, the lymphocytes from umDC-sensitized mice displayed a strong response for the stimulation of allotype cells *in vitro*, these data demonstrated that CTLA4-Ig modified DCs could induce T cell anergy and evoke the peripheral tolerance against specific antigens.

In order to assess the effect of mDCs on allotype islet transplantation, the islet cells of BALB/c mice were planted into the kidney capsules of C57BL/6 mice and the gene-modified DCs were intravenously administered simultaneously. Consequently, injection of mDCs could evidently prolong the graft survival. By daily monitoring PG levels, we found that the PG levels could decrease to lower than 11.1 mmol/L from a higher level. These phenomena happened in the mice treated with mDC 3 days after islet transplantation and maintained more than 2 weeks. However, in the control mice, 5 days after transplantation, their PG continued increase gradually to the level more than 11.1 mmol/L. In addition, we detected serum IFN- γ and IL-4 on days 5 and 15, the results showed that the level of IFN- γ decreased and IL-4 increased in mDC treated recipient mice. These indicated that

a deviation of Th1/Th2 occurred. The HE stain of the IDDM murine renal specimens after 7 days islet transplantation showed that there were numerous islet cells in the renal slices in the normoglycemic mice and their cellular structure was intact with a sparse inflammatory cells infiltration. These results suggested that administration of mDCs would improve the outcome of islet transplantation by inhibiting T-lymphocyte proliferation and inducing the immune tolerance.

Injection of mDCs after transplantation could induce the immune tolerance against allotype antigens effectively. The mechanisms may include: mDCs directly present the antigens to cytotoxic T lymphocytes (CTL), MHC homologous CTL recognizes antigens and obtains the first signal. The mDCs secrete CTLA4-Ig to block CD28/B7 costimulatory pathway or to supply a negative costimulatory signal, then inhibit the further activation of allotype T cells or induces their anergy; the negative costimulatory molecules and cytokines which down-regulate the Th1 activity may inhibit the activation and proliferation of specific MHC-restricted T cells, then inhibit the recipient immune response to allotype antigens. By secreting the negative costimulatory molecules, mDCs inhibit the activation and proliferation of allotype lymphocytes as well as autotype T cells against the islet β cells, thereby induce the allotype tolerance and restructure the autotolerance [26–28].

In summary, our studies demonstrate that CTLA4-Ig modified DCs can prolong graft survival in islet transplantation by the inhibition of T cell proliferation and induction of T cell apoptosis. It may lead a novel strategy to treat diabetes.

Acknowledgement

This work was mainly supported by the National Natural Science foundation(No.30671954), China.

References

- [1] Ryan EA, Lakey JB, Paty BW, Imes S, Korbutt GS, Kneteman NM, et al. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. *Diabetes* 2002;51(7):2148–57.
- [2] Saito H, Frleta D, Dubsky P, Palucka AK. Dendritic cell-based vaccination against cancer. *Hematol Oncol Clin North Am* 2006;20(3):689–710.
- [3] Buonocore S, Flamand V, Goldman M, Braun MY. Bone marrow-derived immature dendritic cells prime *in vivo* alloreactive T cells for interleukin-4-dependent

- rejection of major histocompatibility complex class II antigen-disparate cardiac allograft. *Transplantation* 2003;75(3):407–13.
- [4] Thomson AW, Lu L. Dendritic cells as regulators of immune reactivity: implications for transplantation. *Transplantation* 1999;68(1):1–8.
 - [5] Novak N. Targeting dendritic cells in allergen immunotherapy. *Immunol Allergy Clin North Am* 2006;26(2):307–19.
 - [6] Munz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. *J Exp Med* 2005;202(2):203–7.
 - [7] Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. *J Exp Med* 2001;194(6):863–9.
 - [8] Gong N, Pleyer U, Yang J, Vogt K, Hill M, Anegón I, et al. Influence of local and systemic CTLA4-Ig gene transfer on corneal allograft survival. *J Gene Med* 2006;8(4):459–67.
 - [9] Luo G, Wu J, Chen X, He W, Yi S, Xie Z, et al. CTLA4-Ig introduced by adenovirus vector locally to prolong the survival of xenogeneic skin grafts on rat burn wounds. *J Trauma* 2005;59(5):1209–15.
 - [10] Schmitz V, Neumann UP, Fischer U, Langrehr J, Neuhaus P. Induction of long-term graft acceptance by a combination treatment of donor splenocytes and CTLA4-Ig in a high responder rat liver transplantation model. *Transpl Int* 2005;18(10):1187–96.
 - [11] Potiron N, Chagneau C, Boeffard F, Souillou JP, Anegón I, Le Mauff B. Adenovirus-mediated CTLA4-Ig or CD40lg gene transfer delays pancreatic islet rejection in a rat-to-mouse xenotransplantation model after systemic but not local expression. *Cell Transplant* 2005;14(5):263–75.
 - [12] Gabra BH, Sirois P. Beneficial effect of chronic treatment with the selective bradykinin B1 receptor antagonists, R-715 and R-954, in attenuating streptozotocin-diabetic thermal hyperalgesia in mice. *Peptides* 2003;24(8):1131–9.
 - [13] Salgame P, Varadhachary AS, Primiano LL, Fincke JE, Muller S, Monestier M. An ELISA for detection of apoptosis. *Nucleic Acids Res* 1997;25(3):680–1.
 - [14] Linetsky E, Bottino R, Lehmann R, Alejandro R, Inverardi L, Ricordi C. Improved human islet isolation using a new enzyme blend liberase. *Diabetes* 1997;46(7):1120–3.
 - [15] Osorio RW, Ascher NL, Melzer JS, Stock PG. [Beta]2-microglobulin gene disruption prolongs murine islet allograft survival in NOD mice. *Transplant Proc* 1994;26(7):752.
 - [16] Bertera1 S, Crawford ML, Alexander AM, Papworth GD, Watkins SC, Robbins PD, et al. Gene transfer of manganese superoxide dismutase extends islet graft function in a mouse model of autoimmune diabetes. *Diabetes* 2003;52(2):387–93.
 - [17] Tatarkiewicz K, Hollister-Lock J, Quicquel RR, Colton CK, Bonner-Weir S, Weir GC. Reversal of hyperglycemia in mice after subcutaneous transplantation of macroencapsulated islet. *Transplantation* 1999;67(5):665–71.
 - [18] Reijonen H, Mallone R, Heninger AK, Laughlin EM, Kochik SA, Falk B, et al. GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes. *Diabetes* 2004;53(8):1987–94.
 - [19] Yoon JW, Yoon CS, Lim HW, Huang QQ, Kang Y, Pyun KH, et al. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in β cells. *Science* 1999;284(5417):1183–7.
 - [20] Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, et al. Multiple immunoregulatory defects in type-1 diabetes. *J Clin Invest* 2002;109(1):131–40.
 - [21] Loke P, Allison JP. Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells. *Arthritis Res Ther* 2004;6(5):208–14.
 - [22] Borriello F, Sethna MP, Boyd SD, Schweitzer AN, Tivol EA, Jacoby D, et al. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. *Immunity* 1997;6(3):303–13.
 - [23] Zhu M, Wei MF, Liu F, Shi HF, Wang G. Interleukin-10 modified dendritic cells induce allo-hyporesponsiveness and prolong small intestine allograft survival. *World J Gastroenterol* 2003;9(11):2509–12.
 - [24] Takayama T, Kaneko K, Morelli AE, Li W, Tahara H, Thomson AW. Retroviral delivery of transforming growth factor-beta1 to myeloid dendritic cells: inhibition of T-cell priming ability and influence on allograft survival. *Transplantation* 2002;74(1):112–9.
 - [25] Takayama T, Nishioka Y, Lu L, Lotze MT, Tahara H, Thomson AW. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. *Transplantation* 1998;66(12):1567–74.
 - [26] Seung E, Mordes JP, Greiner DL, Rossini AA. Induction of tolerance for islet transplantation for type 1 diabetes. *Curr Diab Rep* 2003;3(4):329–35.
 - [27] Gao W, Demirci G, Li XC. Negative T cell costimulation and islet tolerance. *Diabetes Metab Res Rev* 2003;19(3):179–85.
 - [28] Bykovskaia SN, Shurin GV, Graner S, Bunker ML, Olson W, Thomas R, et al. Differentiation of immunostimulatory stem cell and monocyte-derived dendritic cells involves maturation of intracellular compartments responsible for antigen presentation and secretion. *Stem Cells* 2002;20(5):380–93.